Although pharmacological treatment is successful in smoking cessation, what are the factors that reduce patients compliance to drugs

Yıl 2020, Cilt: 3 Sayı: 3, 155 - 161, 31.12.2020

Pelin Duru Çetinkaya , Perihan Çetinkaya Kevser Melek

Öz

Objectives: Pharmacological treatment has been shown to increase success in moderate and high nicotine addicts.Although the success of quitting is even higher with three months of regular treatment, the rates of using the treatment are low.In this study, although it was emphasized that patients should use 3 months of regular treatment, the reasons for not using pharmacological treatment were investigated. Methods: One year after the initiation of smoking cessation treatment, the patients were called at least 3 times, and a questionnaire was conducted with the verbal consent of 281 patients. Results: A total of 277 (%70.1) of 395 cases included in the study were male and their mean age was 41.35 ± 11.6 (18--79) years.When the duration of treatment use of 281 cases was questioned, it was seen that only 108 (38.4%) completed the treatment. Some patients not used the drugs due to side effects of the drugs (30.6%), some patients (20.2%) thought that the medication will not be effective, some patients (19.7%) thought that they weren't ready to quit, some patients (16.2%) thought that they quit smoking already. Considering the rate of quitting after one year, it was found that 33.8% of them quit smoking. Conclusion: Although studies have shown that 3 months of regular pharmacological treatment in smoking cessation treatment increases the success of quitting and decreases relapse, it was found that 61.6% of the patients did not use the treatment for three month.

Anahtar Kelimeler

Treatment Compliance, Pharmacological Treatment, Nicotine Addiction, Bupropion, Varenicline

Although pharmacological treatment is successful in smoking cessation, what are the factors that reduce patients compliance to drugs

Öz

Anahtar Kelimeler

Nicotine Addiction, Pharmacological Treatment

Kaynakça

• 1. Dilektaşlı, A.G., Bostan P.P., .., & Salepçi, B. (2020). Turkey and Tobacco Control. Sted. 29, special issue, 36-42. 2. Bilir, N. (2009). Level of tobacco control in Turkey. Turkish Thoracic Journal, 10, 31-34. 3. Law on the Prevention of Harmful Effects of Tobacco Products, No 4207, Official Gazette No. 22829 of 26 November 1996 (inTurkish). https://www.resmigazete.gov.tr/eskiler/2008/01/20080119-1.htm 4. Elbek, O. (2010). National Legislation on Tobacco Control. Ed: Aytemur, Z.A., Akçay, Ş., Elbek, O. Tobacco and Tobacco Control. Toraks books. Issue 10. Aves Publishing, 52-73. 5. Akçay, M.Ş. (2012). Sigara Bırakma Polikliniklerinin Yapılandırılması. Türkiye Klinikleri Göğüs Hastalıkları-Özel Konular, 5(2), 29-34. 6. Çetinkaya, P. D., Batum, Ö., Kararmaz, E. A., Turan, A., Çetinkaya, P., & Çetinkaya, F. (2020). Compliance With The Legislation Of The Smoking Cessation Clinic In Turkey. Turkish Thoracic Journal. 7. Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., ... & Evins, A. E. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet, 387(10037), 2507-2520. 8. Abdul-Kader, J., Airagnes, G., D'almeida, S., Limosin, F., & Le Faou, A. L. (2018). Interventions for smoking cessation in 2018. Revue de pneumologie clinique, 74(3), 160. 9. Kılınç O. (2010) Behavioral and cognitive methods in smoking cessation treatment. Tobacco and Tobacco Control, 2nd ed.(Eds Aytemur ZA, Akçay Ş, Elbek O), 479-484. 10. Demir T. (2010) Constitutions of smoking cessation clinics. Tobacco and Tobacco Control, 2nd ed.(Eds Aytemur ZA, Akçay Ş, Elbek O), 439-444. 11. Larzelere, M. M., & Williams, D. E. (2012). Promoting smoking cessation. American family physician, 85(6), 591-598. 12. Marlow, S. P., & Stoller, J. K. (2003). Smoking cessation. Respiratory care, 48(12), 1238-1256. 13. Shearer, J., & Shanahan, M. (2006). Cost effectiveness analysis of smoking cessation interventions. Australian and New Zealand journal of public health, 30(5), 428-434. 14. Çelik, İ., Yüce, D., Hayran, M., Erman, M., Kılıçkap, S., Buzgan, T., ... & Akdağ, R. (2015). Nationwide smoking cessation treatment support program–Turkey project. Health Policy, 119(1), 50-56. 15. Hollands, G. J., Naughton, F., Farley, A., Lindson, N., & Aveyard, P. (2019). Interventions to increase adherence to medications for tobacco dependence. Cochrane Database of Systematic Reviews, (8). 16. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England journal of medicine, 353(5), 487-497. 17. Lindberg, M. J., Andersen, S. E., Christensen, H. R., & Kampmann, J. P. (2008). Compliance to drug prescriptions. Ugeskrift for laeger, 170(22), 1912. 18. Morphett, K., Partridge, B., Gartner, C., Carter, A., & Hall, W. (2015). Why don’t smokers want help to quit? A qualitative study of smokers’ attitudes towards assisted vs.unassisted quitting. International journal of environmental research and public health, 12(6), 6591-6607. 19. Ekpu, V. U., & Brown, A. K. (2015). The economic impact of smoking and of reducing smoking prevalence: review of evidence. Tobacco use insights, 8, TUI-S15628.